Psoriatic Arthritis News

Patients with inflammatory rheumatic disease, but especially those with autoimmune conditions, as well as those treated with rituximab, may be at greater risk for severe COVID-19 pneumonia than the general population, according to data.

COVID-19 is more severe, with more complications and higher mortality, than influenza among patients with autoimmune disease, according to data published in Rheumatology.

Anxiety and depression symptoms reduce the likelihood of achieving sustained minimal disease activity in psoriatic arthritis, according to data published in Arthritis Care & Research.

Patients on methotrexate for psoriasis or psoriatic arthritis were more likely to develop liver complications than those taking it for rheumatoid arthritis, according to a study.

The FDA has extended its review period for the supplemental new drug application of AbbVie’s upadacitinib for active psoriatic arthritis to allot more time to examine its risk-benefit profile, according to a company press release.

Patients with nail psoriasis may be more likely to develop psoriatic arthritis and should be closely monitored for predictive signs, according to a study.

Patient voices are growing louder in rheumatology. The calls for shared decision-making and a dual target strategy of assessing disease remission are increasing with a body of evidence showing that when patient needs are met, outcomes improve.

This episode details how psoriatic arthritis and the spondyloarthropathies came to be recognized as a distinct clinical entity after decades of nerdy arguing.

Twitter use revealed “early signals” of drug rationing and other critical behavior changes in patients with rheumatic diseases as they navigated the early months of the COVID-19 pandemic, according to data published in Rheumatology.

During the early months of the COVID-19 pandemic, increased all-cause mortality in patients with rheumatoid arthritis and other inflammatory joint diseases largely mirrored that of the general population, according to data.